Williams Mullen Represents Qnovia, Inc. in its $16 Million Series B Financing

The Williams Mullen team consisting of David Lay and Cathy Zhang represented Qnovia, Inc. in its $16 million Series B Preferred Stock financing. Qnovia is a pharmaceutical company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes, including its RespiRx™ Nicotine Inhaler.  

For more information on this transaction, please click here.